TD Cowen Forecasts Strong Price Appreciation for Humana (NYSE:HUM) Stock

Humana (NYSE:HUM) had its price target hoisted by equities researchers at TD Cowen from $370.00 to $430.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “hold” rating on the insurance provider’s stock. TD Cowen‘s price target would suggest a potential downside of 3.11% from the stock’s current price.

HUM has been the topic of several other reports. Bank of America raised shares of Humana from a “neutral” rating to a “buy” rating and set a $500.00 target price on the stock in a research note on Wednesday, July 29th. Zacks Research lowered Humana from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Evercore raised Humana from an “in-line” rating to an “outperform” rating and set a $480.00 price target for the company in a report on Wednesday, July 29th. Robert W. Baird raised Humana from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $390.00 to $596.00 in a report on Friday, October 9th. Finally, Guggenheim increased their price target on Humana from $471.00 to $521.00 and gave the stock a “buy” rating in a research report on Monday. Twenty-one analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Humana has an average rating of “Moderate Buy” and an average target price of $472.17.

Humana Stock Performance

Shares of HUM traded up $5.76 during trading hours on Wednesday, hitting $443.82. The stock had a trading volume of 655,404 shares, compared to its average volume of 1,643,430. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.74 and a current ratio of 1.65. The firm has a 50-day moving average price of $405.76 and a 200 day moving average price of $313.90. Humana has a fifty-two week low of $163.11 and a fifty-two week high of $456.50. The firm has a market capitalization of $53.29 billion, a price-to-earnings ratio of 43.21, a PEG ratio of 2.46 and a beta of 0.65.

Humana (NYSE:HUM) last released its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The company had revenue of $41.16 billion for the quarter, compared to analyst estimates of $40.87 billion. During the same quarter last year, the business earned $3.24 earnings per share. The firm’s revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, research analysts anticipate that Humana will post 9.57 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Humana during the 2nd quarter valued at approximately $4,138,160,000. Pzena Investment Management LLC acquired a new position in Humana in the 2nd quarter valued at about $1,749,014,000. Assenagon Asset Management S.A. grew its holdings in shares of Humana by 20,126.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock valued at $479,053,000 after purchasing an additional 1,249,272 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of Humana during the second quarter worth $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in Humana during the 2nd quarter worth about $314,922,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.